Shares of Zymeworks Inc. (NYSE:ZYME) have been given an average recommendation of “Buy” by the nine analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $51.33.
ZYME has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded Zymeworks from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 11th. HC Wainwright restated a “buy” rating and set a $44.00 price target on shares of Zymeworks in a research report on Monday. Finally, Raymond James set a $74.00 price target on Zymeworks and gave the company a “strong-buy” rating in a research report on Monday, September 13th.
In other news, CEO Ali Tehrani sold 3,800 shares of the firm’s stock in a transaction dated Thursday, July 15th. The stock was sold at an average price of $36.00, for a total transaction of $136,800.00. Following the transaction, the chief executive officer now directly owns 264,125 shares of the company’s stock, valued at $9,508,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 5.14% of the stock is currently owned by company insiders.
Shares of ZYME stock opened at $33.07 on Tuesday. Zymeworks has a 52-week low of $24.82 and a 52-week high of $59.03. The company has a market capitalization of $1.53 billion, a PE ratio of -7.60 and a beta of 0.98. The business’s fifty day moving average is $33.39 and its 200 day moving average is $32.77.
Zymeworks (NYSE:ZYME) last issued its quarterly earnings data on Wednesday, August 4th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.26). Zymeworks had a negative return on equity of 57.78% and a negative net margin of 1,073.23%. The business had revenue of $1.77 million during the quarter, compared to analysts’ expectations of $7.26 million. Sell-side analysts predict that Zymeworks will post -4.62 earnings per share for the current fiscal year.
Zymeworks Company Profile
Zymeworks, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S.
Recommended Story: Conference Calls and Individual Investors
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.